Teligent Past Earnings Performance
Past criteria checks 0/6
Teligent's earnings have been declining at an average annual rate of -70.9%, while the Pharmaceuticals industry saw earnings growing at 8.5% annually. Revenues have been declining at an average rate of 16.5% per year.
Key information
-70.9%
Earnings growth rate
78.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | -16.5% |
| Return on equity | n/a |
| Net Margin | -197.8% |
| Last Earnings Update | 30 Jun 2021 |
Recent past performance updates
Revenue & Expenses Breakdown
How Teligent makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 21 | 46 | -92 | 27 | 8 |
| 31 Mar 21 | 49 | -93 | 27 | 8 |
| 31 Dec 20 | 45 | -122 | 27 | 8 |
| 30 Sep 20 | 51 | -47 | 23 | 0 |
| 30 Jun 20 | 55 | -54 | 22 | 11 |
| 31 Mar 20 | 60 | -43 | 22 | 11 |
| 31 Dec 19 | 66 | -25 | 21 | 11 |
| 30 Sep 19 | 67 | -34 | 21 | 0 |
| 30 Jun 19 | 67 | -31 | 21 | 0 |
| 31 Mar 19 | 64 | -40 | 22 | 0 |
| 31 Dec 18 | 66 | -36 | 21 | 0 |
| 30 Sep 18 | 64 | -28 | 21 | 0 |
| 30 Jun 18 | 57 | -33 | 22 | 0 |
| 31 Mar 18 | 57 | -21 | 21 | 0 |
| 31 Dec 17 | 60 | -15 | 20 | 0 |
| 30 Sep 17 | 63 | -15 | 19 | 0 |
| 30 Jun 17 | 68 | -8 | 16 | 0 |
| 31 Mar 17 | 69 | -10 | 15 | 0 |
| 31 Dec 16 | 63 | -12 | 15 | 0 |
| 30 Sep 16 | 62 | -13 | 13 | 0 |
| 30 Jun 16 | 57 | -13 | 12 | 0 |
| 31 Mar 16 | 49 | -1 | 11 | 0 |
| 31 Dec 15 | 44 | 7 | 11 | 0 |
| 30 Sep 15 | 45 | 19 | 9 | 0 |
Quality Earnings: TLGT.Q is currently unprofitable.
Growing Profit Margin: TLGT.Q is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if TLGT.Q's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare TLGT.Q's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TLGT.Q is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-17.3%).
Return on Equity
High ROE: TLGT.Q's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.